ID: ALA244946

Max Phase: Preclinical

Molecular Formula: C31H35N7S

Molecular Weight: 537.74

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ccc2c(-c3nnc(SCCCN4CCc5ccc(-c6cc(C)nn6C)cc5CC4)n3C)cccc2n1

Standard InChI:  InChI=1S/C31H35N7S/c1-21-9-12-26-27(7-5-8-28(26)32-21)30-33-34-31(36(30)3)39-18-6-15-38-16-13-23-10-11-25(20-24(23)14-17-38)29-19-22(2)35-37(29)4/h5,7-12,19-20H,6,13-18H2,1-4H3

Standard InChI Key:  WIHMMKGUBDZGEG-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 537.74

Molecular Weight (Monoisotopic): 537.2675

AlogP: 5.63

#Rotatable Bonds: 7

Polar Surface Area: 64.66

Molecular Species: BASE

HBA: 8

HBD: 0

#RO5 Violations: 2

HBA (Lipinski): 7

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 9.34

CX LogP: 4.90

CX LogD: 2.97

Aromatic Rings: 5

Heavy Atoms: 39

QED Weighted: 0.20

Np Likeness Score: -1.75

References

1. Micheli F, Bonanomi G, Blaney FE, Braggio S, Capelli AM, Checchia A, Curcuruto O, Damiani F, Fabio RD, Donati D, Gentile G, Gribble A, Hamprecht D, Tedesco G, Terreni S, Tarsi L, Lightfoot A, Stemp G, Macdonald G, Smith A, Pecoraro M, Petrone M, Perini O, Piner J, Rossi T, Worby A, Pilla M, Valerio E, Griffante C, Mugnaini M, Wood M, Scott C, Andreoli M, Lacroix L, Schwarz A, Gozzi A, Bifone A, Ashby CR, Hagan JJ, Heidbreder C..  (2007)  1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists.,  50  (21): [PMID:17867665] [10.1021/jm0705612]

2. Micheli F, Bonanomi G, Braggio S, Capelli AM, Damiani F, Di Fabio R, Donati D, Gentile G, Hamprecht D, Perini O, Petrone M, Tedesco G, Terreni S, Worby A, Heidbreder C..  (2008)  New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,  18  (3): [PMID:18178090] [10.1016/j.bmcl.2007.12.042]

3. Holmes IP, Micheli F, Gaines S, Lorthioir O, Watson SP, Fabio RD, Gentile G, Heidbreder C, Savoia C, Worby A..  (2009)  Dopamine D3 receptor antagonists: the quest for a potentially selective PET ligand. Part one: lead identification.,  19  (16): [PMID:19560918] [10.1016/j.bmcl.2009.06.043]

4. Bennacef I, Salinas CA, Bonasera TA, Gunn RN, Audrain H, Jakobsen S, Nabulsi N, Weinzimmer D, Carson RE, Huang Y, Holmes I, Micheli F, Heidbreder C, Gentile G, Rossi T, Laruelle M..  (2009)  Dopamine D3 receptor antagonists: the quest for a potentially selective PET ligand. Part 3: Radiosynthesis and in vivo studies.,  19  (17): [PMID:19635669] [10.1016/j.bmcl.2009.07.055]

5. Micheli F, Arista L, Bonanomi G, Blaney FE, Braggio S, Capelli AM, Checchia A, Damiani F, Di-Fabio R, Fontana S, Gentile G, Griffante C, Hamprecht D, Marchioro C, Mugnaini M, Piner J, Ratti E, Tedesco G, Tarsi L, Terreni S, Worby A, Ashby CR, Heidbreder C..  (2010)  1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists.,  53  (1): [PMID:19891474] [10.1021/jm901319p]

Source

Source(1):

• Scientific Literature